Drug
AVL-3288
AVL-3288 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Completed1
Terminated1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
completed133%
terminated133%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
withdrawnphase_1
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
NCT03281694
completedphase_1
Clinical Trial of AVL-3288 in Schizophrenia Patients
NCT02978599
terminatedphase_1
Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
NCT01851603
Clinical Trials (3)
Showing 3 of 3 trials
NCT03281694Phase 1
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
NCT02978599Phase 1
Clinical Trial of AVL-3288 in Schizophrenia Patients
NCT01851603Phase 1
Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3